John R. Wetterau
Eli Lilly (United States)(US)
Publications by Year
Research Areas
Peroxisome Proliferator-Activated Receptors, Lipid metabolism and biosynthesis, Cancer, Lipids, and Metabolism, Diabetes, Cardiovascular Risks, and Lipoproteins, Lipoproteins and Cardiovascular Health
Most-Cited Works
- → Absence of Microsomal Triglyceride Transfer Protein in Individuals with Abetalipoproteinemia(1992)758 cited
- → Discovery of Dapagliflozin: A Potent, Selective Renal Sodium-Dependent Glucose Cotransporter 2 (SGLT2) Inhibitor for the Treatment of Type 2 Diabetes(2008)617 cited
- → Cloning and gene defects in microsomal triglyceride transfer protein associated with abetalipoproteinaemia(1993)503 cited
- → Dapagliflozin, a Selective SGLT2 Inhibitor, Improves Glucose Homeostasis in Normal and Diabetic Rats(2008)417 cited
- → Protein disulfide isomerase is a component of the microsomal triglyceride transfer protein complex.(1990)367 cited
- → The Role of the Microsomal Triglygeride Transfer Protein in Abetalipoproteinemia(2000)306 cited